Patrick F Smith

Summary

Affiliation: F. Hoffmann-La Roche Ltd

Publications

  1. ncbi Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection
    Patrick F Smith
    Hoffman La Roche Inc, Clinical Pharmacology, Nutley, NJ 07110 1199, USA
    Antimicrob Agents Chemother 51:3574-81. 2007
  2. ncbi Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals
    Patrick F Smith
    Pharmacology Support Laboratory, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, 219 Cooke Hall, Buffalo, NY 14260, USA
    Clin Pharmacokinet 44:99-109. 2005
  3. ncbi Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors
    Patrick F Smith
    Adult ACTG Pharmacology Support Laboratory, Laboratory for Antiviral Research, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 12460, USA
    Antimicrob Agents Chemother 49:3558-61. 2005
  4. ncbi Development of a pharmacokinetic and Bayesian optimal sampling model for individualization of oral busulfan in hematopoietic stem cell transplantation
    Julie M Bullock
    Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Ther Drug Monit 28:62-6. 2006
  5. ncbi Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors
    Qing Ma
    University at Buffalo, Pharmacotherapy Research Center, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 317 Hochstetter Hall, Buffalo, NY 14260, USA
    Expert Opin Drug Metab Toxicol 1:473-85. 2005
  6. ncbi Drug interactions between proton pump inhibitors and antiretroviral drugs
    Sarah M McCabe
    Associate Dean, Clinical Education and Research, University of Buffalo, Department of Pharmacy Practice, 317 Hochstetter Hall, Buffalo, NY 14260, USA
    Expert Opin Drug Metab Toxicol 3:197-207. 2007
  7. ncbi Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects
    Ying Jun Cao
    Division of Clinical Pharmacology, Johns Hopkins University, Baltimore, Maryland 21287 5554, USA
    Pharmacotherapy 28:863-74. 2008

Collaborators

Detail Information

Publications7

  1. ncbi Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection
    Patrick F Smith
    Hoffman La Roche Inc, Clinical Pharmacology, Nutley, NJ 07110 1199, USA
    Antimicrob Agents Chemother 51:3574-81. 2007
    ..45 log(10), with individual patients having reductions of greater than 0.7 log(10). No bevirimat resistance mutations were detected during the course of the study...
  2. ncbi Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals
    Patrick F Smith
    Pharmacology Support Laboratory, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, 219 Cooke Hall, Buffalo, NY 14260, USA
    Clin Pharmacokinet 44:99-109. 2005
    ..Our objective was to characterise the population pharmacokinetics of delavirdine in HIV-infected patients who participated in the adult AIDS Clinical Trials Group (ACTG) 260 and 261 studies...
  3. ncbi Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors
    Patrick F Smith
    Adult ACTG Pharmacology Support Laboratory, Laboratory for Antiviral Research, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 12460, USA
    Antimicrob Agents Chemother 49:3558-61. 2005
    ..There were no significant differences in efavirenz pharmacokinetics...
  4. ncbi Development of a pharmacokinetic and Bayesian optimal sampling model for individualization of oral busulfan in hematopoietic stem cell transplantation
    Julie M Bullock
    Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Ther Drug Monit 28:62-6. 2006
    ..All limited sampling models tested were unbiased in their results, and a 4-sample scheme proved to adequately characterize busulfan pharmacokinetics, and should allow for a reduced sampling frequency for therapeutic drug monitoring...
  5. ncbi Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors
    Qing Ma
    University at Buffalo, Pharmacotherapy Research Center, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, 317 Hochstetter Hall, Buffalo, NY 14260, USA
    Expert Opin Drug Metab Toxicol 1:473-85. 2005
    ..This review provides an updated summary of pharmacokinetic interactions with NNRTIs...
  6. ncbi Drug interactions between proton pump inhibitors and antiretroviral drugs
    Sarah M McCabe
    Associate Dean, Clinical Education and Research, University of Buffalo, Department of Pharmacy Practice, 317 Hochstetter Hall, Buffalo, NY 14260, USA
    Expert Opin Drug Metab Toxicol 3:197-207. 2007
    ..This review summarizes the current knowledge on the interactions between proton pump inhibitors and antiretrovirals, and makes recommendations for the coadministration of proton pump inhibitors...
  7. ncbi Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects
    Ying Jun Cao
    Division of Clinical Pharmacology, Johns Hopkins University, Baltimore, Maryland 21287 5554, USA
    Pharmacotherapy 28:863-74. 2008
    ..To compare steady-state pharmacokinetics and pharmacodynamics of methadone enantiomers when coadministered with fosamprenavir 700 mg-ritonavir 100 mg twice/day...